When was OncoDiag founded?

OncoDiag was founded in 2013 and raised its 1st funding round 5 years after it was founded.

Where is OncoDiag located?

OncoDiag is headquartered in Miserey, France.

Who is the current CEO of OncoDiag?

Claude Hennion of OncoDiag. They have also founded 1 company.

How many employees does OncoDiag have?

As of Sep 30, 2026, the latest employee count at OncoDiag is 8.

Is OncoDiag a funded company?

OncoDiag is a funded company, having raised a total of $4.2M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2018.

When was the latest funding round of OncoDiag?

OncoDiag's latest funding was a $***** Series A round on Mar 15, 2021, with participation from 4 investors.

Where does OncoDiag rank among its competitors?

OncoDiag ranks 20th amongst 107 active competitors, of which 25 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Vesica Health, which secured $4.47M in Mar, 2026.

Who are the top competitors of OncoDiag?

OncoDiag's top competitors include Biocartis, NeuMoDx and QuantuMDx Group. Among them, Vesica Health secured the most recent funding round in March, 2026.

OncoDiag - 2026 Company Profile, Team, Funding & Competitors

OncoDiag is a series A company based in Miserey (France), founded in 2013 by Claude Hennion. It operates as a Developer of non-invasive cancer diagnostic solutions. OncoDiag has raised $4.2M in funding from investors like Les Business Angels des Grandes Écoles, Paris Business Angels and Angels Sante. The company has 107 active competitors, including 25 funded and 20 that have exited. Its top competitors include companies like Biocartis, NeuMoDx and QuantuMDx Group.

Company Details

Developer of non-invasive cancer diagnostic solutions. The Urodiag is a CE_IVD certified noninvasive quantitative real-time PCR test that uses a urine sample to diagnose bladder cancer based on genetic and epigenetic analysis. Another test developed is Colodiag for the early detection of colorectal cancer and Prostadiag test for detection of prostate cancer.

Website: www.oncodiag.fr/
Email ID: *****@oncodiag.fr
Phone Number: +33 **********

Key Metrics

Founded Year

2013

Location

Miserey, France

Stage

Series A

Total Funding

$4.2M in 2 rounds

Latest Funding Round

Series A, Mar 15, 2021, $*****

Investors

Les Business Angels des Grandes Écoles & 4 more

Ranked

20^th among 107 active competitors

Employee Count

8 as on Sep 30, 2026

Similar Companies

Biocartis & 85 more

View OncoDiag's full profile

OncoDiag has raised a total funding of $4.2M over 2 rounds. Its first funding round was on 2018. Its latest funding round was a Series A round on Mar 15, 2021 for $*****. 4 investors participated in its latest round. OncoDiag has 5 institutional investors.

Here is the list of recent funding rounds of OncoDiag:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 15, 2021	5704674	Series A	5552531	9988233	5890482	5689547
2018	5008	Seed	6008	1767	5346	4345

Access funding benchmarks and valuations. Sign up today!

View details of OncoDiag's funding rounds and investors

The founders of OncoDiag is Claude Hennion. Claude Hennion is the CEO of OncoDiag.

Here are the details of OncoDiag's key team members:

Claude Hennion: Co-Founder & President & CEO of OncoDiag.

View details of OncoDiag's Founder profiles and Board Members

OncoDiag's employee count trend

OncoDiag has 8 employees as of Sep 26. Here is OncoDiag's employee count trend over the years:

Uncover OncoDiag's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OncoDiag include Biocartis, NeuMoDx and QuantuMDx Group. Here is the list of Top 10 competitors of OncoDiag, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biocartis 2007, Mechelen (Belgium), Public	Manufacturer of automated molecular diagnostic systems for oncology biomarker testing	$305M	Johnson & Johnson Innovation – JJDC, Advent Life Sciences ... & 18 others	58/100
2nd	NeuMoDx 2012, Ann Arbor (United States), Acquired	Developer of a platform for low cost molecular testing	$66M	Arboretum Ventures, Wolverine Venture Fund ... & 3 others	52/100
3rd	QuantuMDx Group 2008, Newcastle Upon Tyne (United Kingdom), Series D	Manufacturer of molecular diagnostic platforms and assays for infectious diseases	$57.3M	Adjuvo, WG Partners & 3 others	49/100
4th	Quantalife 2008, Pleasanton (United States), Acquired	Life science research and clinical diagnostics solutions provider, powering possibilities	$28.7M	Paladin Capital, Vital Venture Capital & 3 others	48/100
5th	Co-Dx 2013, Salt Lake City (United States), Public	Provider of genomics-based information and solutions for transplant patients	$1.1M	NIH, SALSS	48/100
6th	VitaDX 2015, Evry Courcouronnes (France), Series B	Early diagnostics for bladder cancer	$23.3M	Odyssee Venture, BNP Paribas & 9 others	48/100
7th	Bigtec Labs 2000, Bengaluru (India), Funding Raised	Developer of point-of-care solutions for nucleic acid amplification tests	-	C-CAMP, Grand Challenges Canada & 3 others	47/100
8th	Vesica Health 2022, Irvine (United States), Acquired	Provider of noninvasive tests to improve the early detection and treatment of bladder cancer for physicians and hematuria patients	$4.47M	-	46/100
9th	Nucleix 2008, Rehovot (Israel), Series C	Developer non-invasive molecular cancer diagnostic tests	$88.5M	RA Capital Management, Sands Capital & 10 others	46/100
10th	Molecular Designs 2019, Birmingham (United States), Funding Raised	Developer of molecular diagnostic kits for the detection of a wide range of diseases	-	Excellere Partners, Excellere	45/100
20th	OncoDiag 2013, Miserey (France), Series A	Developer of non-invasive cancer diagnostic solutions	$4.2M	Paris Business Angels, Angels Sante & 3 others	39/100